Can Renal Denervation Augment Rhythm Control in Atrial Fibrillation?

Area of Science:

• Cardiology
• Electrophysiology
• Interventional Cardiology

Background:

• Pulmonary vein isolation (PVI) is a standard treatment for atrial fibrillation (AF), but long-term success rates can be suboptimal.
• Renal denervation (RDN) is an emerging therapy that targets the sympathetic nervous system.

Purpose of the Study:

• To evaluate the efficacy of combining renal denervation (RDN) with pulmonary vein isolation (PVI) compared to PVI alone for treating atrial fibrillation (AF).
• To assess the impact of RDN + PVI on AF recurrence, disease burden, and safety outcomes.

Main Methods:

• A meta-analysis of 8 randomized controlled trials (RCTs) comparing RDN + PVI versus PVI alone in patients with AF.
• Systematic literature search of MEDLINE, Embase, and Clinicaltrials.gov.
• Data analysis using Comprehensive R Archive Network software with a Mantel-Haenszel random-effects model.

Main Results:

• No significant difference in AF recurrence (RR, 0.75; P = 0.1212), freedom from AF (RR, 1.25; P = 0.2235), or antiarrhythmic drug discontinuation (RR, 1.85; P = 0.0864) between groups.
• Significant reduction in arrhythmia burden (SMD, -1.17; P = 0.0271), major adverse cardiac events (RR, 0.33; P = 0.0029), and left atrial diameter (SMD, -3.22; P = 0.0372) in the RDN + PVI group.
• No significant differences in all-cause mortality, stroke, bleeding, or procedural complications.

Conclusions:

• Renal denervation combined with pulmonary vein isolation does not significantly improve AF recurrence or freedom from AF rates compared to PVI alone.
• The combination therapy shows promise in reducing overall arrhythmia burden, major adverse cardiac events, and left atrial size.
• Further research is warranted to clarify the role of RDN in AF management.